Olpha, the leading pharmaceutical manufacturer in the Baltics, has expanded it’s over the counter (OTC) product portfolio with the launch of a new medicine for the short-term relief of pain. The product is now available in pharmacies across the Baltic States and the Czech Republic, becoming the eighth medicine introduced under the company’s new product portfolio.
According to epidemiological data, nearly half (47%) of the European Union’s population regularly experiences mild to moderate pain, including headaches, back pain, toothaches, menstrual pain and other common pain conditions. This highlights that physical discomfort is not an occasional occurrence but a daily reality for millions of people. Even when not severe, recurring pain can significantly affect quality of life by reducing concentration, lowering productivity, disrupting sleep and contributing to emotional stress.
“Our new medicine is the first pain relief product in Olpha’s new OTC portfolio and marks an important milestone in the further development of this business segment. We are committed to broadening patients’ access to high-quality healthcare solutions while strengthening pharmaceutical manufacturing in the Baltics and developing competitive products for European markets,” said Dr. Chem. Juris Hmeļņickis, Chairman of the Management Board of Olpha.
The launch further strengthens Olpha’s OTC portfolio, reflecting the company’s strategic focus on developing accessible treatments for common health conditions that affect people’s everyday lives. From initial concept to commercial launch in European pharmacies, the development of the new medicine took three years.
Following the change in its majority shareholders, Olpha adopted a new growth strategy focused on expanding its presence in Western European markets. Since then, the company has made significant progress in broadening its product portfolio. To date, 46 products have been submitted for registration in Western European markets, of which 35 have already received regulatory approval in European countries. Overall, Olpha has obtained 198 national marketing authorisations across European Union Member States and the United Kingdom.
At the same time, the company continues to expand its portfolio of registered products in Ukraine, the Balkan region, Georgia and Mexico. Eight medicines from Olpha’s new product portfolio have already been successfully launched in Western European markets.
